Giampaolo Merlini

List of Publications by Citations

644 papers	38,742 citations	97 h-index	181 g-index
747 ext. papers	46,615 ext. citations	5.1 avg, IF	7.27 L-index

#	Paper	IF	Citations
644	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
643	International uniform response criteria for multiple myeloma. *Leukemia*, **2006**, 20, 1467-73	10.7	1996
642	Molecular mechanisms of amyloidosis. *New England Journal of Medicine*, **2003**, 349, 583-96	59.2	1335
641	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *American Journal of Hematology*, **2005**, 79, 319-28	7.1	971
640	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *New England Journal of Medicine*, **2018**, 379, 1007-1016	59.2	859
639	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*, **2016**, 133, 2404-12	16.7	792
638	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *New England Journal of Medicine*, **2018**, 379, 22-31	59.2	618
637	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
636	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, **2009**, 23, 215-24	10.7	559
635	New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9	2.2	553
634	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*, **2010**, 24, 1121-7	10.7	505
633	Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. *Circulation*, **2009**, 120, 1203-12	16.7	471
632	Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2013**, 310, 2658-67	27.4	424
631	Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. *Circulation*, **2003**, 107, 2440-5	16.7	390
630	IMWG consensus on risk stratification in multiple myeloma. *Leukemia*, **2014**, 28, 269-77	10.7	387
629	Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2016**, 23, 209-213	2.7	369
628	Amyloidosis: pathogenesis and new therapeutic options. *Journal of Clinical Oncology*, **2011**, 29, 1924-33	2.2	349

627	Dangerous small B-cell clones. *Blood*, **2006**, 108, 2520-30	2.2	318
626	Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. *Blood*, **2004**, 103, 2936-8	2.2	316
625	International prognostic scoring system for Waldenstrom macroglobulinemia. *Blood*, **2009**, 113, 4163-70	2.2	282
624	Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 215-219	2.7	278
623	Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2005**, 12, 1-4	2.7	274
622	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, **2013**, 121, 3420-7	2.2	267
621	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. *Blood*, **2014**, 124, 2325-32	2.2	265
620	Diagnosis of monoclonal gammopathy of renal significance. *Kidney International*, **2015**, 87, 698-711	9.9	261
619	A primer of amyloid nomenclature. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2007**, 14, 179-83	2.7	255
618	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Seminars in Oncology*, **2003**, 30, 116-20	5.5	254
617	Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2010**, 17, 101-4	2.7	252
616	Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. *Journal of the American College of Cardiology*, **2015**, 66, 2451-2466	15.1	250
615	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia*, **2012**, 26, 2317-25	10.7	247
614	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *Journal of Clinical Oncology*, **2013**, 31, 2347-57	2.2	245
613	Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. *Arthritis and Rheumatism*, **2008**, 58, 1516-20		245
612	Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation. *Protein Science*, **2000**, 9, 831-45	6.3	242
611	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. *Blood*, **2015**, 126, 612-5	2.2	232
610	Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *Journal of Clinical Oncology*, **2010**, 28, 1031-7	2.2	226

609	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*, **2013**, 27, 780-91	10.7	222
608	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. *Blood*, **2006**, 107, 3854-8	2.2	209
607	Systemic immunoglobulin light chain amyloidosis. *Nature Reviews Disease Primers*, **2018**, 4, 38	51.1	207
606	Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. *Kidney International*, **1998**, 54, 650-71	9.9	205
605	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. *Journal of Clinical Oncology*, **2016**, 34, 1544-57	2.2	204
604	Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19, 167-70	2.7	193
603	Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia*, **2012**, 26, 595-608	10.7	189
602	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nature Reviews Nephrology*, **2019**, 15, 45-59	14.9	189
601	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. *European Heart Journal*, **2013**, 34, 520-8	9.5	181
600	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). *Blood*, **2005**, 105, 2949-51	2.2	180
599	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. *Circulation*, **2019**, 139, 431-443	16.7	180
598	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia*, **2014**, 28, 525-42	10.7	179
597	Eprodisate for the treatment of renal disease in AA amyloidosis. *New England Journal of Medicine*, **2007**, 356, 2349-60	59.2	177
596	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. *British Journal of Haematology*, **2013**, 160, 171-6	4.5	173
595	Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. *Journal of Clinical Oncology*, **2009**, 27, 120-6	2.2	173
594	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 2959-63	11.5	173
593	The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. *Journal of Internal Medicine*, **2004**, 255, 159-78	10.8	172
592	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. *Circulation: Heart Failure*, **2019**, 12, e006075	7.6	171

591	Systemic light chain amyloidosis: an update for treating physicians. *Blood*, **2013**, 121, 5124-30	2.2	171
590	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, **2009**, 23, 1904-12	10.7	170
589	Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. *Clinical Chemistry*, **2009**, 55, 499-504	5.5	169
588	Clinical aspects of systemic amyloid diseases. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1753, 11-22	4	169
587	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. *Blood*, **2010**, 116, 3426-30	2.2	159
586	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. *Blood*, **2007**, 110, 787-8	2.2	156
585	Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. *Journal of Structural Biology*, **2000**, 130, 280-9	3.4	156
584	Waldenström macroglobulinemia. *Blood*, **2007**, 109, 5096-103	2.2	150
583	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19 Suppl 1, 34-6	2.7	147
582	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. *Journal of Clinical Oncology*, **2016**, 34, 1097-103	2.2	141
581	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. *Blood*, **2011**, 118, 865-73	2.2	141
580	Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood*, **2013**, 122, 3276-82	2.2	135
579	What is new in diagnosis and management of light chain amyloidosis?. *Blood*, **2016**, 128, 159-68	2.2	134
578	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. *Blood*, **2012**, 119, 1844-7	2.2	133
577	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. *Advances in Therapy*, **2015**, 32, 920-8	4.1	131
576	Biomarkers of acute kidney injury. *Advances in Chronic Kidney Disease*, **2008**, 15, 222-34	4.7	131
575	Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. *Blood*, **2002**, 100, 948-53	2.2	130
574	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. *Blood*, **2009**, 114, 1489-97	2.2	129

573	Treatment recommendations from the Eighth International Workshop on Waldenstrm's Macroglobulinemia. *Blood*, **2016**, 128, 1321-8	2.2	125
572	Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. *Journal of Translational Medicine*, **2010**, 8, 74	8.5	124
571	A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. *Journal of Biological Chemistry*, **2001**, 276, 46714-21	5.4	124
570	Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 217-222	2.7	123
569	A practical approach to the diagnosis of systemic amyloidoses. *Blood*, **2015**, 125, 2239-44	2.2	120
568	Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 419-26	5.9	120
567	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. *Blood*, **1995**, 86, 855-861	2.2	117
566	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 108-114	2.7	115
565	Structure, function and amyloidogenic propensity of apolipoprotein A-I. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2006**, 13, 191-205	2.7	111
564	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica*, **2014**, 99, 743-50	6.6	109
563	Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. *Journal of Cardiovascular Translational Research*, **2013**, 6, 1011-20	3.2	109
562	Treatment recommendations for patients with Waldenstrm macroglobulinemia (WM) and related disorders: IWWM-7 consensus. *Blood*, **2014**, 124, 1404-11	2.2	107
561	Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. *Molecular and Cellular Proteomics*, **2008**, 7, 1570-83	7.6	107
560	Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. *Blood*, **1994**, 83, 2939-2945	2.2	104
559	4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. *FASEB Journal*, **2003**, 17, 803-9	0.9	103
558	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. *Blood*, **1980**, 55, 1011-1019	2.2	103
557	The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. *American Journal of Pathology*, **1999**, 155, 695-702	5.8	101
556	Beta2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. *FEBS Journal*, **1998**, 258, 61-7		98

555	Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2006**, 6, 380-3		98
554	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. *Leukemia*, **2014**, 28, 2311-6	10.7	97
553	A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. *Blood*, **2014**, 123, 3543-52	2.2	97
552	Holter monitoring in AL amyloidosis: prognostic implications. *PACE - Pacing and Clinical Electrophysiology*, **2001**, 24, 1228-33	1.6	97
551	Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. *American Journal of Physiology - Heart and Circulatory Physiology*, **2013**, 305, H95-103	5.2	95
550	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. *Blood*, **2018**, 132, 1478-1485	2.2	93
549	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. *Neurology and Therapy*, **2016**, 5, 1-25	4.6	91
548	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. *Blood*, **2017**, 130, 597-605	2.2	89
547	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. *Journal of Hematology and Oncology*, **2018**, 11, 10	22.4	89
546	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2021**, 42, 1554-1568	9.5	88
545	Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Blood*, **2017**, 130, 625-631	2.2	86
544	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood*, **2020**, 136, 71-80	2.2	86
543	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 142-50	2.7	84
542	Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. *Neurology*, **2015**, 85, 675-82	6.5	83
541	Immunoglobulin light chain amyloidosis. *Expert Review of Hematology*, **2014**, 7, 143-56	2.8	83
540	Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. *Arthritis and Rheumatism*, **2009**, 61, 1435-40		81
539	Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. *Seminars in Oncology*, **2003**, 30, 211-5	5.5	80
538	The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. *Blood*, **2012**, 119, 144-50	2.2	79

537	Amyloidosis in autoinflammatory syndromes. *Autoimmunity Reviews*, **2012**, 12, 14-7	13.6	79
536	Monoclonal gammopathies. *BMC Geriatrics*, **2010**, 10,	4.1	78
535	Bortezomib in the treatment of AL amyloidosis: targeted therapy?. *Haematologica*, **2007**, 92, 1302-7	6.6	78
534	AL amyloidosis: from molecular mechanisms to targeted therapies. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 1-12	3.1	77
533	The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. *Journal of Molecular Biology*, **2008**, 378, 887-97	6.5	76
532	Treatment of cardiac transthyretin amyloidosis: an update. *European Heart Journal*, **2019**, 40, 3699-3706	9.5	75
531	Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. *Journal of Biological Chemistry*, **2003**, 278, 2444-51	5.4	75
530	Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. *British Journal of Haematology*, **1996**, 93, 789-94	4.5	75
529	Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. *Therapeutic Drug Monitoring*, **2005**, 27, 785-92	3.2	72
528	A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. *Annals of Neurology*, **2005**, 58, 639-44	9.4	72
527	The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. *American Journal of Hematology*, **2017**, 92, 772-779	7.1	71
526	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *American Journal of Hematology*, **2012**, 87, 465-71	7.1	70
525	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. *Annals of Hematology*, **2012**, 91, 89-92	3	70
524	Outrageous prices of orphan drugs: a call for collaboration. *Lancet, The*, **2018**, 392, 791-794	40	69
523	Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. *Annals of the Rheumatic Diseases*, **2011**, 70, 1511-2	2.4	69
522	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. *Nature Communications*, **2019**, 10, 1269	17.4	68
521	Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. *European Journal of Nuclear Medicine and Molecular Imaging*, **1995**, 22, 1393-401		68
520	A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. *Blood*, **2017**, 129, 2120-2123	2.2	66

519	Gender-related risk of myocardial involvement in systemic amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2008**, 15, 40-8	2.7	66
518	AA amyloidosis: basic knowledge, unmet needs and future treatments. *Swiss Medical Weekly*, **2012**, 142, w13580	3.1	66
517	Amyloidosis and Waldenstrm's macroglobulinemia. *Hematology American Society of Hematology Education Program*, **2004**, 2004, 257-82	3.1	65
516	The lung in amyloidosis. *European Respiratory Review*, **2017**, 26,	9.8	64
515	Differential diagnosis of monoclonal gammopathy of undetermined significance. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 595-603	3.1	64
514	Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3680-6	12.7	64
513	Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. *Journal of Clinical Oncology*, **2005**, 23, 4662-8	2.2	64
512	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. *Seminars in Arthritis and Rheumatism*, **2014**, 43, 818-23	5.3	62
511	Multiple myeloma. *Annals of Oncology*, **2010**, 21 Suppl 7, vii143-50	10.3	62
510	Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. *British Journal of Haematology*, **1990**, 74, 65-9	4.5	62
509	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica*, **2013**, 98, 433-6	6.6	61
508	Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. *Clinica Chimica Acta*, **2005**, 357, 168-72	6.2	61
507	First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. *Arthritis and Rheumatism*, **2004**, 50, 2966-9		61
506	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. *British Journal of Haematology*, **2001**, 113, 1044-6	4.5	61
505	Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. *Seminars in Oncology*, **1986**, 13, 350-65	5.5	61
504	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *Journal of Neurology*, **2021**, 268, 2109-2122	5.5	61
503	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. *New England Journal of Medicine*, **2021**, 385, 46-58	59.2	61
502	Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. *Journal of the Peripheral Nervous System*, **2011**, 16, 119-29	4.7	60

501	Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. *Clinical Chemistry*, **2010**, 56, 1880-8	5.5	60
500	Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 457-458	5.5	59
499	A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. *Blood*, **2020**, 135, 1531-1540	2.2	59
498	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. *Gastroenterology*, **2004**, 126, 1416-22	13.3	59
497	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, **2018**, 32, 1883-1898	10.7	58
496	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. *Annals of Hematology*, **2009**, 88, 347-50	3	57
495	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2019**, 25, e1-e39	3.3	56
494	The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. *Blood*, **2017**, 129, 2132-2142	2.2	55
493	Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. *Annals of Noninvasive Electrocardiology*, **2013**, 18, 271-80	1.5	55
492	Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants. *British Journal of Haematology*, **1989**, 73, 221-7	4.5	55
491	The workings of the amyloid diseases. *Annals of Medicine*, **2007**, 39, 200-7	1.5	54
490	Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. *Clinical Cancer Research*, **2005**, 11, 1786-90	12.9	54
489	Neuropathies associated with monoclonal gammopathies. *Neuromuscular Disorders*, **1996**, 6, 3-18	2.9	54
488	Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. *Hematological Oncology*, **1990**, 8, 23-30	1.3	53
487	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. *Leukemia*, **2016**, 30, 1979-1986	10.7	52
486	Amyloidosis: is a cure possible?. *Annals of Oncology*, **2008**, 19 Suppl 4, iv63-6	10.3	51
485	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 439-445	12.7	50
484	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. *European Journal of Heart Failure*, **2007**, 9, 808-13	12.3	50

483	Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. *Clinical Chemistry*, **2003**, 49, 1554-5	5.5	50
482	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. *Blood*, **2014**, 124, 2498-506	2.2	49
481	Topological investigation of amyloid fibrils obtained from beta2-microglobulin. *Protein Science*, **2002**, 11, 2362-9	6.3	49
480	Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. *Protein Science*, **2005**, 14, 696-702	6.3	49
479	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circulation: Heart Failure*, **2017**, 10,	7.6	48
478	Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. *European Journal of Heart Failure*, **2021**, 23, 277-285	12.3	48
477	Sjgren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?. *Arthritis and Rheumatism*, **2008**, 58, 1992-9		47
476	Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. *Rheumatology*, **2005**, 44, 1074-5	3.9	47
475	Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection. *Blood*, **1998**, 91, 2948-2954	9.2	47
474	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. *Journal of Clinical Oncology*, **2016**, 34, 2037-45	2.2	46
473	Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. *Stem Cells*, **2012**, 30, 1465-76	5.8	46
472	Autoantibody activity in Waldenstrom's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2005**, 5, 225-9		46
471	Light and electron microscopy immunohistochemical characterization of amyloid deposits. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1997**, 4, 157-170	2.7	45
470	Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. *European Respiratory Journal*, **2008**, 32, 153-61	13.6	45
469	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. *American Journal of Clinical Nutrition*, **2006**, 83, 350-4	7	45
468	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer Journal*, **2020**, 10, 102	7	45
467	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. *Basic Research in Cardiology*, **2013**, 108, 378	11.8	44
466	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 80-2	2.7	44

465	Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". *Current Medicinal Chemistry*, **2004**, 11, 1065-84	4.3	44
464	4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. *American Journal of Pathology*, **2000**, 156, 1919-25	5.8	44
463	Management of AL amyloidosis in 2020. *Blood*, **2020**, 136, 2620-2627	2.2	44
462	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. *FASEB Journal*, **2015**, 29, 4614-28	0.9	43
461	CyBorD: stellar response rates in AL amyloidosis. *Blood*, **2012**, 119, 4343-5	2.2	43
460	Current treatment of AL amyloidosis. *Haematologica*, **2009**, 94, 1044-8	6.6	43
459	Treatment of primary amyloidosis. *Seminars in Hematology*, **1995**, 32, 60-79	4	43
458	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
457	Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. *Journal of Proteome Research*, **2013**, 12, 5642-55	5.6	42
456	Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. *Journal of Molecular Biology*, **2011**, 407, 465-76	6.5	42
455	A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 24-30	2.7	42
454	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. *Protein Science*, **2001**, 10, 187-99	6.3	42
453	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. *British Journal of Haematology*, **2016**, 175, 77-86	4.5	41
452	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. *Journal of Clinical Oncology*, **2020**, 38, 3252-3260	2.2	41
451	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). *Haematologica*, **2004**, 89, 717-41	6.6	41
450	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. *Blood*, **2017**, 129, 456-459	2.2	40
449	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Journal of Cardiac Failure*, **2019**, 25, 854-865	3.3	40
448	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. *JAMA Cardiology*, **2019**, 4, 466-472	16.2	40

447	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. *Leukemia*, **2019**, 33, 254-257	10.7	40
446	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. *Expert Opinion on Investigational Drugs*, **2014**, 23, 1239-51	5.9	40
445	Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2005**, 12, 120-6	2.7	40
444	Therapeutic advances demand accurate typing of amyloid deposits. *American Journal of Medicine*, **2001**, 111, 243-4	2.4	40
443	Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. *American Heart Journal*, **1995**, 130, 528-36	4.9	40
442	Acute phase proteins and prognosis in multiple myeloma. *British Journal of Haematology*, **1993**, 83, 595-601	4.9	40
441	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. *Scientific Reports*, **2016**, 6, 29096	4.9	40
440	Biology and therapy of immunoglobulin deposition diseases. *Hematology/Oncology Clinics of North America*, **1997**, 11, 89-110	3.1	39
439	The molecular interaction of 4?-iodo-4?-deoxydoxorubicin with Leu-55Pro transthyretin amyloid-like oligomer leading to disaggregation. *Biochemical Journal*, **2000**, 351, 273-279	3.8	39
438	Treatment of AL Amyloidosis with 4?-Iodo-4?-Deoxydoxorubicin: An Update. *Blood*, **1999**, 93, 1112-1113	2.2	39
437	TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. *Neurological Sciences*, **2013**, 34, 1057-63	3.5	38
436	Occurrence of monoclonal components in general practice: clinical implications. *European Journal of Haematology*, **1992**, 48, 192-5	3.8	38
435	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 701-8	8.8	38
434	Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. *Chest*, **2008**, 134, 101-8	5.3	38
433	Light Chain Amyloidosis. *Mediterranean Journal of Hematology and Infectious Diseases*, **2018**, 10, e2018022	3.2	37
432	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. *Scientific Reports*, **2017**, 7, 15661	4.9	37
431	Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. *British Journal of Haematology*, **2017**, 179, 748-755	4.5	37
430	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. *QJM - Monthly Journal of the Association of Physicians*, **2011**, 104, 957-70	2.7	37

429	AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. *Clinical Lymphoma and Myeloma*, **2009**, 9, 80-3		37
428	Guidelines for the analysis of Bence Jones protein. *Clinical Chemistry and Laboratory Medicine*, **2003**, 41, 338-46	5.9	37
427	First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). *PLoS ONE*, **2013**, 8, e73443	3.7	37
426	Prognostic value of fragmented QRS in cardiac AL amyloidosis. *International Journal of Cardiology*, **2013**, 167, 2156-61	3.2	36
425	Assessing mNIS+7 and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. *Muscle and Nerve*, **2017**, 56, 901-911	3.4	35
424	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. *Blood*, **2018**, 131, 1568-1575	2.2	35
423	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Journal of Heart Failure*, **2021**, 23, 512-526	12.3	35
422	Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. *Blood*, **2018**, 131, 525-532	2.2	35
421	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *British Journal of Haematology*, **2017**, 176, 728-742	4.5	34
420	The Diflunisal Trial: study accrual and drug tolerance. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19 Suppl 1, 37-8	2.7	34
419	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2011**, 1814, 409-19	4	34
418	Proteomics of beta2-microglobulin amyloid fibrils. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1753, 23-33	4	34
417	Serum amyloid A, procalcitonin, and C-reactive protein in early assessment of severity of acute pancreatitis. *Digestive Diseases and Sciences*, **2000**, 45, 1072-8	4	34
416	The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. *Haematologica*, **1999**, 84, 218-21	6.6	34
415	Systemic amyloidosis: novel therapies and role of biomarkers. *Nephrology Dialysis Transplantation*, **2017**, 32, 770-780	4.3	33
414	Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. *Leukemia*, **2017**, 31, 1735-1742	10.7	32
413	Rare diseases and effective treatments: are we delivering?. *Lancet, The*, **2015**, 385, 750-2	40	32
412	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-B pathway. *Arthritis Research and Therapy*, **2015**, 17, 93	5.7	32

411	Genetic microheterogeneity of human transthyretin detected by IEF. *Electrophoresis*, **2007**, 28, 2053-64	3.6	32
410	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. *American Journal of Hematology*, **1994**, 46, 189-93	7.1	32
409	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Blood*, **2016**, 128, 646-646	2.2	32
408	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31
407	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. *Scientific Reports*, **2017**, 7, 16809	4.9	31
406	A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. *Journal of Clinical Immunology*, **1984**, 4, 185-96	5.7	31
405	The clinical implications of monoclonal immunoglobulins. *Seminars in Oncology*, **1986**, 13, 366-79	5.5	31
404	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 8360-8369	11.5	30
403	Clotting alterations in primary systemic amyloidosis. *Haematologica*, **2000**, 85, 289-92	6.6	30
402	Clinical proteomics for diagnosis and typing of systemic amyloidoses. *Proteomics - Clinical Applications*, **2013**, 7, 136-43	3.1	29
401	Transplantation vs. conventional-dose therapy for amyloidosis. *Current Opinion in Oncology*, **2011**, 23, 214-20	4.2	29
400	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). *Blood*, **2019**, 134, 139-139	2.2	29
399	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2002**, 9, 108-14	2.7	29
398	Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. *Haematologica*, **2006**, 91, 1635-43	6.6	29
397	Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. *Antioxidants and Redox Signaling*, **2017**, 27, 567-582	8.4	28
396	Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. *Annals of Noninvasive Electrocardiology*, **2013**, 18, 327-35	1.5	28
395	Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?. *British Heart Journal*, **2002**, 88, 615-21		28
394	Differential diagnosis of monoclonal gammopathy of undetermined significance. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 595-603	3.1	28

393	A revised international prognostic score system for Waldenström's macroglobulinemia. *Leukemia*, **2019**, 33, 2654-2661	10.7	27
392	Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry. *Stroke*, **2016**, 47, 1702-9	6.7	27
391	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. *Annals of Hematology*, **2012**, 91, 399-406	3	27
390	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Annals of Hematology*, **2012**, 91, 875-88	3	27
389	Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. *American Journal of Pathology*, **2001**, 158, 1599-603	5.8	27
388	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. *American Journal of Hematology*, **2018**, 93, E368-E370	7.1	26
387	Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. *Expert Review of Molecular Diagnostics*, **2014**, 14, 55-66	3.8	26
386	Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 143-5	2	26
385	Standardizing plasma protein measurements worldwide: a challenging enterprise. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 1567-75	5.9	26
384	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2007**, 14, 133-40	2.7	26
383	Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. *Therapeutic Drug Monitoring*, **1984**, 6, 25-30	3.2	26
382	Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. *Metabolism: Clinical and Experimental*, **1982**, 31, 1100-4	12.7	26
381	Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. *Nephrology Dialysis Transplantation*, **2012**, 27, 3713-8	4.3	25
380	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 259-265	2.7	25
379	Therapy and management of systemic AL (primary) amyloidosis. *Swiss Medical Weekly*, **2006**, 136, 715-20	3.1	25
378	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 1734-1743	5.9	24
377	Novel strategies for the diagnosis and treatment of cardiac amyloidosis. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 1195-211	2.5	24
376	Monitoring free light chains in serum using mass spectrometry. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1073-83	5.9	24

375	Serum prealbumin: an independent marker of short-term energy intake in the presence of multiple-organ disease involvement. *Nutrition*, **2013**, 29, 580-2	4.8	24
374	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 213-216	2.7	24
373	Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. *European Journal of Neurology*, **2020**, 27, 1374-1381	6	23
372	Monoclonal IgM-related AL amyloidosis. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 241-248	4.2	23
371	Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. *Canadian Journal of Cardiology*, **2012**, 28, 537-41	3.8	23
370	Protein aggregation. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1065-75	5.9	23
369	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. *BMC Family Practice*, **2020**, 21, 198	2.6	23
368	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. *Lancet Neurology, The*, **2021**, 20, 49-59	24.1	23
367	Systemic amyloidoses: what an internist should know. *European Journal of Internal Medicine*, **2013**, 24, 729-39	3.9	22
366	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 216-21	2.7	22
365	Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils. *FEBS Journal*, **1997**, 249, 21-6		22
364	Infertility and hypergonadotropic hypogonadism as first evidence of hereditary apolipoprotein A-I amyloidosis. *Journal of Urology*, **2007**, 178, 344-8	2.5	22
363	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. *Protein Science*, **2007**, 16, 343-9	6.3	22
362	Current concepts on the pathogenesis of systemic amyloidosis. *Nephrology Dialysis Transplantation*, **1996**, 11 Suppl 9, 53-62	4.3	22
361	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 87-93	6.9	21
360	Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. *Journal of Investigative Dermatology*, **2003**, 121, 308-14	4.3	21
359	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. *Blood*, **2018**, 132, 1988-1991	2.2	20
358	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 173-8	2.7	20

357	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. *Kidney International*, **2015**, 87, 1223-9	9.9	20
356	Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2011**, 18 Suppl 1, 92-3	2.7	20
355	Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1991**, 1097, 177-82	6.9	20
354	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. *Blood*, **1995**, 86, 855-61	2.2	20
353	Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response. *Blood*, **2016**, 128, 3261-3261	2.2	20
352	Human osteogenic differentiation in Space: proteomic and epigenetic clues to better understand osteoporosis. *Scientific Reports*, **2019**, 9, 8343	4.9	19
351	Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. *Nutrition*, **2015**, 31, 1228-34	4.8	19
350	Waldenström macroglobulinemia. *Hematology/Oncology Clinics of North America*, **2014**, 28, 945-70	3.1	19
349	The red cell distribution width (RDW): value and role in preterm, IUGR (intrauterine growth restricted), full-term infants. *Hematology*, **2014**, 19, 365-9	2.2	19
348	Diagnostic performance of triggering receptor expressed on myeloid cells-1 and CD64 index as markers of sepsis in preterm newborns. *Pediatric Critical Care Medicine*, **2013**, 14, 178-82	3	19
347	The diflunisal trial: update on study drug tolerance and disease progression. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 196-7	2.7	19
346	Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). *Biology of Blood and Marrow Transplantation*, **2008**, 14, 6-11	4.7	19
345	Detection and identification of monoclonal components: immunoelectrophoresis on agarose gel and immunofixation on cellulose acetate compared.. *Clinical Chemistry*, **1981**, 27, 1862-1865	5.5	19
344	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. *Blood Cancer Journal*, **2021**, 11, 34	7	19
343	Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. *Haematologica*, **1995**, 80, 409-15	6.6	19
342	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. *Analytical Chemistry*, **2019**, 91, 2894-2900	7.8	18
341	Biochemical markers in early diagnosis and management of systemic amyloidoses. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 1517-31	5.9	18
340	Neuropathies associated with monoclonal gammapathies. *Haematologica*, **1994**, 79, 557-66	6.6	18

339	International Prognostic Scoring System (IPSS) for Waldenstro m Macroglobulinemia (WM).. *Blood* , **2006**, 108, 127-127	2.2	18
338	When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. *Blood Advances*, **2019**, 3, 212-215	7.8	18
337	Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 1095-1110	6.4	17
336	Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. *Journal of Hypertension*, **2014**, 32, 1121-31; discussion 1131	1.9	17
335	Paraprotein interference in an assay of conjugated bilirubin. *Clinical Chemistry*, **2005**, 51, 1076-7	5.5	17
334	Hereditary amyloidosis. *New England Journal of Medicine*, **2002**, 347, 1206-7; author reply 1206-7	59.2	17
333	Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. *Bone Marrow Transplantation*, **1999**, 23, 323-7	4.4	17
332	Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. *Analytical Biochemistry*, **1996**, 239, 107-9	3.1	17
331	A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. *PLoS ONE*, **2013**, 8, e76022	3.7	17
330	Immunoglobulin Light Chain Systemic Amyloidosis. *Cancer Treatment and Research*, **2016**, 169, 273-318	3.5	17
329	Novel Therapies in Light Chain Amyloidosis. *Kidney International Reports*, **2018**, 3, 530-541	4.1	16
328	Heavy chain disease can be detected by capillary zone electrophoresis. *Clinical Chemistry*, **2005**, 51, 247-9	5.5	16
327	Biological features of the clone involved in primary amyloidosis (AL). *Leukemia*, **2001**, 15, 195-202	10.7	16
326	The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. *Biochemical Journal*, **2000**, 351, 273-9	3.8	16
325	Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1996**, 1317, 161-7	6.9	16
324	Complete remission in plasma cell leukaemia. *British Journal of Haematology*, **1986**, 62, 525-7	4.5	16
323	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. *Blood*, **1980**, 55, 1011-9	2.2	16
322	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). *Blood*, **2014**, 124, 3450-3450	2.2	16

321	Management of AL amyloidosis in 2020. *Hematology American Society of Hematology Education Program*, **2020**, 2020, 363-371	3.1	16
320	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 41	7	16
319	The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 191-9	2.7	15
318	Development and preparation of a new serum protein reference material: feasibility studies and processing. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 805-13	5.9	15
317	A multi-fpga 10x-real-time high-speed search engine for a 5000-word vocabulary speech recognizer **2009**,		15
316	Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. *Journal of Virology*, **2007**, 81, 4564-71	6.6	15
315	Molecular mechanisms of amyloidosis. *New England Journal of Medicine*, **2003**, 349, 1872-3; author reply 1872-3	59.2	15
314	Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2004**, 1690, 33-41	6.9	15
313	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. *Blood*, **2019**, 134, 3166-3166	2.2	15
312	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. *Blood*, **2010**, 116, 1364-1364	2.2	15
311	High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. *American Journal of Hematology*, **2020**, 95, 900-905	7.1	15
310	Therapies for cardiac light chain amyloidosis: An update. *International Journal of Cardiology*, **2018**, 271, 152-160	3.2	15
309	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. *Journal of Leukocyte Biology*, **2016**, 99, 761-9	6.5	14
308	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. *Clinica Chimica Acta*, **2011**, 412, 1262-5	6.2	14
307	Mechanisms of renal damage in plasma cell dyscrasias: an overview. *Contributions To Nephrology*, **2007**, 153, 66-86	1.6	14
306	The Pavia approach to clinical protein analysis. *Clinical Chemistry and Laboratory Medicine*, **2001**, 39, 1025-8	3.9	14
305	Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1999**, 6, 273-7	2.7	14
304	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 97-102	2.7	14

303	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. *Blood*, **2020**, 135, 293-296	2.2	13
302	New concepts in the treatment and diagnosis of amyloidosis. *Expert Review of Hematology*, **2018**, 11, 117-127	2.8	13
301	Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. *Clinica Chimica Acta*, **2012**, 413, 544-7	6.2	13
300	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 64-6	2.7	13
299	Treatment of painful bone lesions and hypercalcemia. *European Journal of Haematology*, **1989**, 51, 135-9	3.8	13
298	Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18, 87-90	2.7	13
297	Peptichemio induction therapy in myelomatosis. *Cancer Chemotherapy and Pharmacology*, **1982**, 8, 9-16	3.5	13
296	Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Advances*, **2020**, 4, 1321-1324	7.8	13
295	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. *Journal of Biological Chemistry*, **2020**, 295, 16572-16584	5.4	13
294	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. *Mediators of Inflammation*, **2020**, 2020, 8562485	4.3	13
293	Management of the elderly patient with AL amyloidosis. *European Journal of Internal Medicine*, **2018**, 58, 48-56	3.9	13
292	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. *American Journal of Physiology - Heart and Circulatory Physiology*, **2019**, 316, H1158-H1166	5.2	12
291	Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. *Neurology and Therapy*, **2020**, 9, 105-115	4.6	12
290	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. *Journal of Neuroinflammation*, **2017**, 14, 115	10.1	12
289	Pathogenesis of renal failure in multiple myeloma: any role of contrast media?. *BioMed Research International*, **2014**, 2014, 167125	3	12
288	Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment. *Journal of Parenteral and Enteral Nutrition*, **2014**, 38, 891-4	4.2	12
287	Risk stratification in Waldenström macroglobulinemia. *Expert Review of Hematology*, **2012**, 5, 187-99	2.8	12
286	Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. *Journal of Hepatology*, **1998**, 29, 879-86	13.4	12

285	Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma. *Immunology*, **2004**, 112, 420-7	7.8	12
284	Procalcitonin Is Not a Reliable Marker for the Assessment of Severity in Acute Pancreatitis without Infectious Complications. *Clinical Chemistry*, **2000**, 46, 428-430	5.5	12
283	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. *Leukemia*, **2020**, 34, 1187-1191	10.7	12
282	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. *Journal of Neurology*, **2020**, 267, 1070-1079	5.5	12
281	Amyloidosis and Ocular Involvement: an Overview. *Seminars in Ophthalmology*, **2020**, 35, 7-26	2.4	12
280	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *British Journal of Haematology*, **2021**, 194, 496-507	4.5	12
279	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000029	3.9	12
278	Systemic amyloidoses and proteomics: The state of the art. *EuPA Open Proteomics*, **2016**, 11, 4-10	0.1	11
277	The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. *Journal of Internal Medicine*, **1995**, 237, 143-9	10.8	11
276	The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization. *Molecular Immunology*, **1990**, 27, 385-94	4.3	11
275	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. *Blood*, **2012**, 120, 731-731	2.2	11
274	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. *Blood Cancer Journal*, **2020**, 10, 90	7	11
273	How we treat Waldenstrm's macroglobulinemia. *Haematologica*, **2005**, 90, 117-25	6.6	11
272	High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2013**, 20, 48-51	2.7	10
271	Utility of biochemical markers in the follow-up of heart transplant recipients. *Transplantation Proceedings*, **2003**, 35, 3075-8	1.1	10
270	A deiminated viral peptide to detect antibodies in rheumatoid arthritis. *Annals of the New York Academy of Sciences*, **2005**, 1050, 243-9	6.5	10
269	Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. *European Journal of Cancer & Clinical Oncology*, **1986**, 22, 787-91		10
268	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Blood*, **2014**, 124, 35-35	2.2	10

267	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer Journal*, **2021**, 11, 192	7	10
266	Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. *Journal of Molecular Biology*, **2020**, 432, 845-860	6.5	10
265	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. *Frontiers in Pharmacology*, **2020**, 11, 1024	5.6	10
264	Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. *Blood Advances*, **2020**, 4, 4175-4179	7.8	10
263	Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. *Cells*, **2021**, 10,	7.9	10
262	Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. *FEBS Journal*, **2021**,	5.7	10
261	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 56-57	2.7	9
260	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 231-236	2.7	9
259	Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 921-7	5.9	9
258	Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 244-6	2	9
257	Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. *Molecular BioSystems*, **2011**, 7, 651-8		9
256	Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and in vitro diagnostics to generate reliable results. *Proteomics - Clinical Applications*, **2007**, 1, 1016-35	3.1	9
255	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel hot spot' in codon 47. *Clinical Genetics*, **2000**, 57, 284-90	4	9
254	Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. *Cancer Chemotherapy and Pharmacology*, **1993**, 31, 265-8	3.5	9
253	Structural characterization of kappa II Inc, a new amyloid immunoglobulin. *BBA - Proteins and Proteomics*, **1989**, 995, 103-8		9
252	Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies. *Tumori*, **1987**, 73, 445-449		9
251	Differential transplacental binding of valproic acid: influence of free fatty acids. *British Journal of Clinical Pharmacology*, **1984**, 17, 759-62	3.8	9
250	Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. *European Journal of Cancer & Clinical Oncology*, **1984**, 20, 81-90		9

249	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. *BMJ Open*, **2019**, 9, e025483	3	9
248	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. *Journal of Clinical Oncology*, **2021**, 39, 8003-8003	2.2	9
247	Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. *Kidney International*, **2016**, 90, 479-81	9.9	9
246	Evidence that amyloidogenic light chains undergo antigen-driven selection. *Blood*, **1998**, 91, 2948-54	2.2	9
245	Treatment of AL amyloidosis with 4'-Iodo-4'-deoxydoxorubicin: an update. *Blood*, **1999**, 93, 1112-3	2.2	9
244	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 10-14	2.7	8
243	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. *British Journal of Haematology*, **2020**, 190, 346-357	4.5	8
242	The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 939-45	5.9	8
241	Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques. *Autoimmunity Highlights*, **2012**, 3, 79-85	3.7	8
240	Proteomics in protein misfolding diseases. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 627-35	5.9	8
239	Late-onset familial Mediterranean fever: an atypical presentation of dermatologic interest. *Archives of Dermatology*, **2007**, 143, 1080-1		8
238	Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. *Cancer Treatment Reports*, **1985**, 69, 971-5		8
237	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. *Leukemia*, **2021**,	10.7	8
236	The elusive pathogenesis of Schnitzler syndrome. *Blood*, **2018**, 131, 944-946	2.2	7
235	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. *Haematologica*, **2017**, 102, e411-e414	6.6	7
234	A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma. *European Journal of Haematology*, **1991**, 46, 177-81	3.8	7
233	Use of an anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: pathophysiology and clinical implications. *Scandinavian Journal of Immunology*, **1992**, 36, 607-15	3.4	7
232	Hepatitis B virus markers in monoclonal (type I and II) and polyclonal (type III) cryoglobulinemias. *Haematologica*, **1988**, 73, 375-8	6.6	7

231	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. *Blood*, **2020**, 136, 48-50	2.2	7
230	An IgM monoclonal protein with multiple serological specificities. *Clinical and Experimental Immunology*, **1979**, 37, 276-82	6.2	7
229	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. *JACC: Heart Failure*, **2021**, 9, 736-746	7.9	7
228	Systemic amyloidosis: are we moving ahead?. *Netherlands Journal of Medicine*, **2004**, 62, 104-5	0.5	7
227	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. *BMC Medical Genetics*, **2019**, 20, 23	2.1	6
226	A patient with AL amyloidosis with negative free light chain results. *Clinical Chemistry and Laboratory Medicine*, **2016**, 54, 1035-7	5.9	6
225	Determining the significance of MGUS. *Blood*, **2014**, 123, 305-7	2.2	6
224	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e59-e60	2	6
223	Enlightening light chain deposition disease. *Blood*, **2015**, 126, 2770-1	2.2	6
222	Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy. *Clinical Nuclear Medicine*, **2015**, 40, 446-7	1.7	6
221	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2012**, 19 Suppl 1, 11-3	2.7	6
220	Immune mechanisms of AL amyloidosis. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 365-373		6
219	Primary (AL) amyloidosis. *Renal Failure*, **1993**, 15, 429-33	2.9	6
218	A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. *International Journal of Oncology*, **1994**, 5, 833-9	1	6
217	Characterization of the two unique human anti-flavin monoclonal immunoglobulins. *FEBS Journal*, **1995**, 228, 886-93		6
216	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). *Journal of Clinical Oncology*, **2007**, 25, 8050-8050	2.2	6
215	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *Circulation: Cardiovascular Imaging*, **2021**, 14, e000030	3.9	6
214	Familial AL-amyloidosis in three Italian siblings. *Haematologica*, **1996**, 81, 105-9	6.6	6

213	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 64-65	2.7	5
212	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 168-173	2.7	5
211	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans. *Worm*, **2014**, 3, e965590		5
210	Transthyretin, nutrition, and inflammation: response to Dr. Bernstein. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45,	5.9	5
209	Autologous stem cell and kidney transplantation for primary amyloidosis associated with ESRD: which should come first?. *American Journal of Transplantation*, **2005**, 5, 1585-6	8.7	5
208	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. *Nephrology Dialysis Transplantation*, **1996**, 11, 1708-1711	4.3	5
207	Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjgren's syndrome and serum hyperviscosity. *Annals of the Rheumatic Diseases*, **1987**, 46, 938-42	2.4	5
206	Amino acid sequence of the FV region of a human monoclonal IgM (NOV) with specificity for the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1, which cross-reacts with polynucleotides and with denatured DNA. *Journal of Immunology*, **1991**, 147, 915-20	5.3	5
205	Multiple myeloma and related plasma cell dyscrasias. *JAMA - Journal of the American Medical Association*, **1987**, 258, 2930-7	27.4	5
204	The laboratory investigation of monoclonal components. *Haematologica*, **1988**, 73, 79-85	6.6	5
203	Proliferative activity, response to therapy and survival in multiple myeloma. *Haematologica*, **1984**, 69, 148-62	6.6	5
202	Ixazomib-dexamethasone (Ixa-Dex) vs physician choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. *Journal of Clinical Oncology*, **2020**, 38, 8546-8546	2.2	5
201	Imaging of Systemic Amyloidosis **2010**, 15-32		5
200	Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2016**, 245, S113-8	2	5
199	Monoclonal gammapathies. *Journal of the International Federation of Clinical Chemistry*, **1997**, 9, 171-6		5
198	Procalcitonin is not a reliable marker for the assessment of severity in acute pancreatitis without infectious complications. *Clinical Chemistry*, **2000**, 46, 428-30	5.5	5
197	Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster. *Anticancer Research*, **2009**, 29, 2507-12	2.3	5
196	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*,1-13	2.7	5

195	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 68-69	2.7	4
194	Prognostication of survival and progression to dialysis in AA amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 136-137	2.7	4
193	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. *Blood*, **2019**, 134, 320-323	2.2	4
192	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 61-3	2.7	4
191	Utility of bisphosphonates in treating bone metastases. *Medical Oncology*, **1996**, 13, 215-21	3.7	4
190	Peptichemio, Vincristine, Prednisone Induction Treatment in Multiple Myeloma. *Tumori*, **1985**, 71, 581-588	1.7	4
189	Vincristine in the treatment of multiple myeloma. *Haematologica*, **1980**, 65, 595-611	6.6	4
188	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. *Blood*, **2020**, 136, 50-51	2.2	4
187	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. *Blood*, **2008**, 112, 869-869	2.2	4
186	A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis.. *Blood*, **2009**, 114, 2863-2863	2.2	4
185	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. *Blood*, **2010**, 116, 988-988	2.2	4
184	Treatment of AL Amyloidosis with Bendamustine. *Blood*, **2012**, 120, 4057-4057	2.2	4
183	Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case Study. *Lecture Notes in Computer Science*, **2012**, 65-79	0.9	4
182	Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. *Expert Review of Hematology*, **2020**, 13, 1003-1015	2.8	4
181	Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. *Kidney International*, **2019**, 95, 258-260	9.9	4
180	Age-related amyloidosis outside the brain: A state-of-the-art review. *Ageing Research Reviews*, **2021**, 70, 101388	12	4
179	Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. *Haematologica*, **1996**, 81, 110-5	6.6	4
178	Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. *Cancer Treatment and Research*, **2008**, 142, 211-42	3.5	4

177	Regulated expression of amyloidogenic immunoglobulin light chains in mice. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 52-53	2.7	3
176	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 66-67	2.7	3
175	Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. *Proteomics*, **2018**, 18, e1700353	4.8	3
174	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 187-93	2.7	3
173	Embryonic stem and haematopoietic progenitor cells resist to A□oligomer toxicity and maintain the differentiation potency in culture. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2010**, 17, 137-45	2.7	3
172	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 96-7	2.7	3
171	Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. *Clinical Biochemistry*, **2005**, 38, 504-8	3.5	3
170	Conformational dynamics of the beta2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I. *Cellular and Molecular Life Sciences*, **2000**, 57, 675-83	10.3	3
169	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. *Nephrology Dialysis Transplantation*, **1996**, 11, 1708-1711	4.3	3
168	Micropolyspora faeni antigens of three commercial extracts. *Mycopathologia*, **1984**, 84, 165-9	2.9	3
167	Gene expression of pyrogenic cytokines in Hodgkin's disease lymph nodes. *Haematologica*, **1992**, 77, 221-5	6.6	3
166	Alpha heavy chain disease: report of two cases. *Haematologica*, **1985**, 70, 431-6	6.6	3
165	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2019**, 134, 3163-3163	2.2	3
164	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. *Blood*, **2008**, 112, 1689-1689	2.2	3
163	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. *Blood*, **2011**, 118, 995-995	2.2	3
162	Use of the Novel Monoclonal Assay for the Measurement of Circulating Free Light Chain in the Diagnosis, Prognostication of Survival and Assessment of Response to Therapy in AL Amyloidosis. *Blood*, **2012**, 120, 3913-3913	2.2	3
161	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. *Blood*, **2016**, 128, 5690-5690	2.2	3
160	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. *Current Clinical Pathology*, **2015**, 9-29	0.1	3

159	Primary Therapy of Waldenstro m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. *Blood*, **2010**, 116, 1941-1941	2.2	3
158	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. *European Journal of Clinical Investigation*, **2021**, 51, e13598	4.6	3
157	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). *Neurology and Therapy*, **2021**, 10, 753-766	4.6	3
156	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. *Cardiology and Therapy*, **2021**, 10, 481-490	2.8	3
155	Search for AL amyloidosis risk factors using Mendelian randomization. *Blood Advances*, **2021**, 5, 2725-2731	7.18	3
154	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. *Frontiers in Medicine*, **2021**, 8, 668173	4.9	3
153	Advances in proteomic study of cardiac amyloidosis: progress and potential. *Expert Review of Proteomics*, **2016**, 13, 1017-1027	4.2	3
152	A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e40-e41	2	3
151	Nodular macroglossia with combined light chain and beta-2 microglobulin deposition in a long-term dialysis patient. *Journal of Nephrology*, **2001**, 14, 128-31	4.8	3
150	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 54-55	2.7	2
149	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 60-61	2.7	2
148	Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium. *Journal of Cardiac Failure*, **2015**, 21, S63	3.3	2
147	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 105-106	2.7	2
146	The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 107-108	2.7	2
145	Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. *Annals of Hematology*, **2013**, 92, 1133-4	3	2
144	Persistence of Minimal Residual Disease by Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients With AL Amyloidosis. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, e24	2	2
143	Serum markers of myocardial damage in acute pancreatitis: a prospective time course study. *Pancreas*, **2015**, 44, 678-80	2.6	2
142	Can ISSWM be used for making treatment decisions?. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 121-3	2	2

141	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2009**, 16, 115-21	2.7	2
140	The Merlini, Waldenstrm, Jayakar staging system revisited. *European Journal of Haematology*, **1989**, 51, 105-10	3.8	2
139	Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. *European Heart Journal*, **2006**, 27, 1810	9.5	2
138	Refining therapy for AL amyloidosis. *Blood*, **2006**, 108, 3632-3633	2.2	2
137	Calcium antagonists and hormone release. IV. The role of calcium in glucose-stimulated early phase insulin release in vivo. *Journal of Endocrinological Investigation*, **1982**, 5, 121-4	5.2	2
136	Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators. *Acta Haematologica*, **1982**, 67, 255-62	2.7	2
135	Immunochemical characteristics of a particular cryoglobulin. A new cryoglobulin subgroup?. *Clinical and Experimental Rheumatology*, **1991**, 9, 399-402	2.2	2
134	Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. *Tumori*, **1985**, 71, 581-8	1.7	2
133	Electrophoresis: cellulose acetate vs agarose gel, visual inspection vs densitometry. *Clinical Chemistry*, **1981**, 27, 1944-5	5.5	2
132	The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy. *Blood*, **2019**, 134, 1901-1901	2.2	2
131	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. *Blood*, **2020**, 136, 44-45	2.2	2
130	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. *Blood*, **2020**, 136, 6-7	2.2	2
129	Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis.. *Blood*, **2009**, 114, 3889-3889	2.2	2
128	Assessing Proteostasis and Proteasome Stress In Light Chain Amyloidosis. *Blood*, **2010**, 116, 3992-3992	2.2	2
127	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. *Blood*, **2011**, 118, 3977-3977	2.2	2
126	High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors. *Blood*, **2013**, 122, 288-288	2.2	2
125	Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome. *Blood*, **2015**, 126, 1773-1773	2.2	2
124	Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients. *Blood*, **2015**, 126, 190-190	2.2	2

123	Patterns of Relapse after Upfront Therapy in AL Amyloidosis. *Blood*, **2016**, 128, 2140-2140	2.2	2
122	Transthyretin-associated Familial Amyloid Polyneuropathy - Current and Emerging Therapies. *European Neurological Review*, **2012**, 7, 14	0.5	2
121	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. *Blood*, **2021**, 138, 153-153	2.2	2
120	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2005**, 12, 159-163		2
119	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain (AL) amyloidosis patient		2
118	Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro. *Medical Oncology and Tumor Pharmacotherapy*, **1991**, 8, 265-9		2
117	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing Between Two Centres. *Molecules*, **2021**, 26,	4.8	2
116	The Clinical Impact of Proteomics in Amyloid Typing. *Mayo Clinic Proceedings*, **2021**, 96, 1122-1127	6.4	2
115	How I Treat AL Amyloidosis. *Blood*, **2021**,	2.2	2
114	Severity in biliary peritonitis. *Giornale Di Chirurgia*, **2012**, 33, 168-71	2.2	2
113	Future Perspectives. *Hematology/Oncology Clinics of North America*, **2020**, 34, 1205-1214	3.1	1
112	A powerful oral triplet for AL amyloidosis. *British Journal of Haematology*, **2020**, 189, 605-606	4.5	1
111	Waldenstrm Macroglobulinemia. *Hematologic Malignancies*, **2018**, 191-220	0	1
110	Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history. *European Journal of Dermatology*, **2014**, 24, 261-3	0.8	1
109	Cardiac light-chain deposition disease relapsing in the transplanted heart. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 135-137	2.7	1
108	Kidney Involvement in Light Chain Amyloidosis. *Journal of Onco-Nephrology*, **2017**, 1, 110-119	0.2	1
107	An ECG/ECHO comparison between AL and ATTR cardiac amyloidosis at diagnosis. *European Heart Journal*, **2013**, 34, P2991-P2991	9.5	1
106	Recommendations for appropriate serum electrophoresis requests: the Italian approach. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, e117-8	5.9	1

105	Reply to S. Girnius et al. *Journal of Clinical Oncology*, **2013**, 31, 2750-1	2.2	1
104	THU0376 Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). *Annals of the Rheumatic Diseases*, **2013**, 71, 282.3-283	2.4	1
103	Systemic diseases: from amyloidosis to cryoglobulinemia. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 1912-5	6.9	1
102	Amyloidosis presenting with Fabry disease. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 231-2	2.7	1
101	Reducing the amyloid burden through immunotherapy: a major therapeutic advance. *Nephrology Dialysis Transplantation*, **2011**, 26, 1471-3	4.3	1
100	Functional study of autonomic neuropathy in primary (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1996**, 3, 167-172	2.7	1
99	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. *Molecular Immunology*, **2008**, 45, 1519-24	4.3	1
98	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2005**, 12, 159-63		1
97	Perturbations of the Kepler Problem in Global Coordinates: A Program. *Celestial Mechanics and Dynamical Astronomy*, **2001**, 81, 313-319	1.4	1
96	Application of monoclonal anti-idiotypes in the study of AL amyloidosis: therapeutic implications. *Renal Failure*, **1993**, 15, 365-71	2.9	1
95	Treatment of multiple myeloma with vincristine. *Acta Haematologica*, **1980**, 64, 176-8	2.7	1
94	Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis. *Blood*, **2018**, 132, 498-498	2.2	1
93	Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. *Blood*, **2018**, 132, 4803-4803	2.2	1
92	Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. *Blood*, **2018**, 132, 4812-4812	2.2	1
91	FISH reveals chromosomal abnormalities in 41 Patients with Systemic Amyloidosis (AL).. *Blood*, **2010**, 116, 1197-1197	2.2	1
90	First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant. *Blood*, **2013**, 122, 1985-1985	2.2	1
89	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. *Blood*, **2016**, 128, 2957-2957	2.2	1
88	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. *Blood*, **2016**, 128, 648-648	2.2	1

87	A sulfhydryl-rich IgM protein with multiple serological specificities. *Clinical and Experimental Immunology*, **1987**, 69, 148-56	6.2	1
86	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. *Blood*, **2021**, 138, 2720-2720	2.2	1
85	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. *Blood*, **2021**, 138, 2721-2721	2.2	1
84	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. *Blood*, **2021**, 138, 159-159	2.2	1
83	Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10TH International Symposium on Amyloid and Amyloidosis **2004**, 151-153		1
82	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. *Journal of Clinical Pharmacology*, **2021**,	2.9	1
81	Amyloid Typing: Immunoelectron Microscopy **2012**, 249-260		1
80	High Molecular Weight Proteins, Sensitive to Collagenase Digestion are Intimate Constituents of Amyloid Deposits **1991**, 519-522		1
79	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. *Journal of Clinical Oncology*, **2016**, 34, TPS8073-TPS8073	2.2	1
78	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. *Blood*, **2012**, 120, 4074-4074	2.2	1
77	PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE. *HemaSphere*, **2019**, 3, 557	0.3	1
76	High sensitivity M-protein detection in a case of light-chain cardiac amyloidosis without evidence of plasma cell dyscrasia. *American Journal of Hematology*, **2019**, 94, 619-621	7.1	1
75	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. *Journal of Cardiac Failure*, **2021**,	3.3	1
74	A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. *Leukemia and Lymphoma*, **2021**, 1-7	1.9	1
73	In search of the most effective therapy for light chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2021**, 1-2	2.7	1
72	Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. *Oncology*, **2011**, 25, 633, 637-8	1.8	1
71	Multivariate statistical analysis of quantitative serum protein data in populations of Rwanda. *American Journal of Physical Anthropology*, **1981**, 55, 13-20	2.5	0
70	The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis. *Blood*, **2020**, 136, 22-22	2.2	0

69	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. *Blood*, **2021**, 138, 2730-2730	2.2	0
68	MYOCARDIAL SYSTOLIC DYSFUNCTION IN CARDIAC AL AMYLOIDOSIS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION. *Journal of Hypertension*, **2004**, 22, S174-S175	1.9	0
67	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. *Blood*, **2018**, 132, 2026-2026	2.2	0
66	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. *Blood*, **2019**, 134, 3066-3066	2.2	0
65	Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN). *Blood*, **2019**, 134, 1868-1868	2.2	0
64	Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis. *Blood* , **2019**, 134, 1860-1860	2.2	0
63	Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis. *Blood*, **2019**, 134, 3312-3312	2.2	0
62	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. *HemaSphere*, **2019**, 3, 616	0.3	0
61	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.. *Circulation: Heart Failure*, **2022**, CIRCHEARTFAILURE121009038	7.6	0
60	Primary Systemic Amyloidosis. *Hematologic Malignancies*, **2018**, 221-245	0	
59	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma **2018**, 1419-1431.e5		
58	Waldenström Macroglobulinemia **2018**, 617-638		
57	Unusual Manifestations of IgM Monoclonal Gammopathies **2017**, 223-236		
56	Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma138-154		
55	Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy. *European Heart Journal*, **2013**, 34, P2958-P2958	9.5	
54	The role of gender and age in cardiac AL amyloidosis. *European Heart Journal*, **2013**, 34, P2996-P2996	9.5	
53	Is a restrictive LV filling pattern invariably present in restrictive cardiomyopathy? The case of cardiac AL amyloidosis. *European Heart Journal*, **2013**, 34, P2442-P2442	9.5	
52	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. *European Heart Journal*, **2013**, 34, P4239-P4239	9.5	

51	Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma190-215	
50	AMICA: an electronic patient record specifically designed for an amyloidosis network. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 236-8	2.7
49	A workflow management system for the biological samples exchange within the amyloidosis network. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 233-5	2.7
48	Symposium on Amyloid Cardiomyopathy: Diagnosis and Treatment, Pavia, September 21, 1996. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1997**, 4, 296-299	2.7
47	WALDENSTRM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA129-149	
46	Exciting new agents in multiple myeloma. *Blood*, **2006**, 108, 3235-3236	2.2
45	Sharpening therapeutic strategy in AL amyloidosis. *Blood*, **2004**, 104, 1593-1594	2.2
44	Anatomic and Clinical Clues to In Vivo Mechanisms of Amyloidogenesis29-46	
43	Pavia, Italy Symposium. Recent Developments in Amyloidosis, June 1, 1995. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1996**, 3, 57-58	2.7
42	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. *FEBS Journal*, **1995**, 228, 886-893	
41	A case of IgM(kappa) monoclonal gammopathy simulating an IgM-IgG biclonal gammopathy. *Annals of Clinical Biochemistry*, **1990**, 27 (Pt 2), 158-60	2.2
40	Identification of specific plasma proteins determining the agarose gel electrophoresis by the immunosubtraction technique. *Clinical Chemistry and Laboratory Medicine*, **1983**, 21, 841-4	5.9
39	Clinical usefulness of the molecular interpretation of the cellulose acetate serum protein electrophoresis (preliminary communication). *Research in Clinic and Laboratory*, **1980**, 10, 239-42	
38	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. *Blood*, **2020**, 136, 11-11	2.2
37	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. *Blood*, **2020**, 136, 33-34	2.2
36	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. *Blood*, **2021**, 138, 4771-4771	2.2
35	Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies. *Blood*, **2021**, 138, 2673-2673	2.2
34	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. *Blood*, **2021**, 138, 4725-4725	2.2

33	Experience with a Patient-Adapted Approach to Autologous Peripheral Blood Stem Cell Transplantation in Al Amyloidosis **2004**, 109-111	
32	Thalidomide plus Intermediate-Dose Dexamethasone in Refractory/Relapsed Al Patients **2004**, 115-117	
31	Amyloid versus Non-Amyloid Immunoglobulin Deposits **2004**, 133-135	
30	Human Monoclonal Cryocrystalglobulinemia: First Complete Heavy and Light Chain Variable Region Nucleotide Sequences.. *Blood*, **2004**, 104, 1381-1381	2.2
29	Uncommon Conditions Underlying AA Amyloidosis **2004**, 521-523	
28	Amyloid Versus Non-Amyloid Immunoglobulin Deposits **2004**, 133-135	
27	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. *Blood*, **2006**, 108, 5449-5449	2.2
26	A Proteomic Approach to the Study of Systemic Amyloidoses **2007**, 360-362	
25	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis **2007**, 273-274	
24	Clinical Trial for Ttr Amyloidosis Using Diflunisal **2007**, 387-389	
23	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al **2007**, 390-392	
22	Keynote Address: Advances in Systemic Amyloidoses **2007**, 341-346	
21	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone **2007**, 282-282	
20	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients. *Blood*, **2018**, 132, 3264-3264	2.2
19	Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab. *Blood*, **2018**, 132, 1985-1985	2.2
18	Imaging of Myocardial Amyloid Involvement with 99m □Tc Aprotinin **1997**, 191-196	
17	Aprotinin 99mTc Myocardial Scan: Risk Stratification of Cardiac Events in Patients with Al/Attr Amyloidosis **1999**, 479-482	
16	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. *Blood*, **2014**, 124, 305-305	2.2

15	Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome. *Blood*, **2014**, 124, 3361-3361	2.2
14	The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. *Current Clinical Pathology*, **2015**, 323-330	0.1
13	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2
12	High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant.. *Blood*, **2009**, 114, 1782-1782	2.2
11	Pathogenesis of Systemic Amyloidoses **2010**, 49-64	
10	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. *Blood*, **2010**, 116, 3062-3062	2.2
9	Pilot Study with Lenalidomide in Patients with POEMS Syndrome. *Blood*, **2011**, 118, 4612-4612	2.2
8	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis **2012**, 9-29	
7	Amiloidosi **2013**, 127-131	
6	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma **2013**, 83-109	
5	Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients. *Blood*, **2013**, 122, 3087-3087	2.2
4	Waldenström Macroglobulinemia **2014**, 303-329	
3	Redirecting proteoxicity. *Leukemia*, **2020**, 34, 3109-3110	10.7
2	PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY. *HemaSphere*, **2019**, 3, 234-235	0.3
1	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma207-227	